

[全部](#)[新闻](#)[图片](#)[购物](#)[视频](#)[更多 ▾](#)[搜索工具](#)

获得 7 条结果 (用时 0.86 秒)

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者: R Vuppalanchi - 2009 - [被引用次数: 563](#) - [相关文章](#)

Nonalcoholic **fatty liver disease** (NAFLD) is **one** of the most common causes of ... Low titers of **anti**-smooth muscle and **anti**-mitochondrial antibodies may also be ... The NAFLD can be categorized into simple **steatosis** and steatohepatitis (NASH). ... The ELF is essentially the "Original European Liver **Fibrosis**" (OELF) test ...

缺少字词: `kea3 channel senecapae`

Pathogenesis of non-alcoholic fatty liver disease

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者: JK Dowman - 2010 - [被引用次数: 343](#) - [相关文章](#)

2009年11月13日 - Non-alcoholic **fatty liver disease** (NAFLD) represents a spectrum of disease ... and highly active **anti**-retroviral drugs.13–15 **Steatosis** also commonly occurs in ... Figure 1. (a) The traditional 2-hit hypothesis: **steatosis** represents the first and liver **fibrosis**,129 and thus the beneficial **effects** of ACE **inhibitors** ...

缺少字词: `kea3 channel senecapae`

Treatment of non-alcoholic fatty liver disease

<https://www.ncbi.nlm.nih.gov> > NCBI > Literature > PubMed Central (PMC) - [翻译此页](#)

作者: KG Tolman - 2007 - [被引用次数: 55](#) - [相关文章](#)

Non-alcoholic **fatty liver disease** (NAFLD) is defined by the presence of hepatic ... Fat accumulating in the liver has several **effects**: (1) upregulation of ... Hepatic **fibrosis** is promoted by **steatosis** even in the absence of liver cell injury (Reeves et al 1996). Ursodiol (ursodeoxycholic acid) is an **anti**-apoptotic, cyto-protective.



31466-Review-check.docx

Quotes Included
Bibliography Included5%
SIMILAR**Name of Journal:** *World Journal of Gastroenterology***Manuscript NO:** 31466**Manuscript Type:** ORIGINAL ARTICLE*Basic Study***Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, senicapoc, in non-alcoholic liver disease**Paka L *et al.* Senicapoc for NAFLD**Latha Paka, David E Smith, Siobhan McCormack, Ping Zhou, Bin Duan, Jingsong Li, Jiaqi Shi, Yong-Jie Hao, Kai Jiang, Michael Yamin, Itzhak D Goldberg, Prakash Narayan****Abstract****AIM****Match Overview**

1	Internet 56 words crawled on 29-May-2016 channelpedia.epfl.ch	1%
2	Internet 36 words crawled on 09-Jan-2017 onlineibrahim.blogspot.com	1%
3	Crossref 32 words Freise, Christian, Silke Heldwein, Ulrike Erben, Joachim Hoyer, Ralf Köhler, Korinna Jöhrens, Eleonora Patsenke	1%
4	Internet 18 words crawled on 30-May-2008 www.evhei.com	<1%
5	Internet 17 words crawled on 20-Aug-2010 www.jci.org	<1%
6	Internet 12 words crawled on 15-Mar-2010 intl-atvb.ahajournals.org	<1%
7	Internet 12 words crawled on 22-Feb-2017 business.bmei.com	<1%

[全部](#)[新闻](#)[图片](#)[购物](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 44 条结果 (用时 0.93 秒)

The calcium-activated potassium channel KCa3.1 is an important ...

www.nature.com > [Scientific Reports](#) > [Articles](#) - [翻译此页](#)作者: LS Møller - 2016 - [相关文章](#)

2016年6月29日 - Inhibition of **KCa3.1** aggravated liver fibrosis during carbon ... this channel appears to be **anti-fibrotic** and protective during liver injury. ... liver injury and upon progression it undermines **liver function** and initiates portal hypertension. Figure 5: **Effects** of the **KCa3.1 channel inhibitor Senicapoc** in CCl4 ...

Non-alcoholic fatty liver disease | BMC Medicine | Full Text

bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-017-0806-8 - [翻译此页](#)

作者: BA Neuschwander-Tetri - 2017

2017年2月28日 - **Non-alcoholic fatty liver disease** has emerged a major challenge because of it ... we all tend to be impressed by substantial **steatosis** on imaging or liver biopsy. ... 1), the transient storage of fatty acids as inert triglyceride, the primary Effective **anti-NASH** drugs will likely have indirect **antifibrotic effects** by ...

缺少字词: kea3 channel senicapoc

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

<https://www.ncbi.nlm.nih.gov> > [NCBI](#) > [Literature](#) > [PubMed Central \(PMC\)](#) - [翻译此页](#)作者: R Vuppalanchi - 2009 - [被引用次数: 572](#) - [相关文章](#)

Nonalcoholic fatty liver disease (NAFLD) is **one** of the most common causes of ... Low titers of **anti-smooth muscle** and **anti-mitochondrial** antibodies may also be noted The ELF is essentially the "Original European Liver **Fibrosis**" (OELF) test histology in patients with **NASH** although their **favorable effect on steatosis is**

[全部](#)[新闻](#)[图片](#)[购物](#)[视频](#)[更多](#)[设置](#)[工具](#)

获得 7 条结果 (用时 0.63 秒)

The calcium-activated potassium channel KCa3.1 is an important ...

<https://www.ncbi.nlm.nih.gov> › NCBI › Literature › PubMed Central (PMC) - [翻译此页](#)

作者 : LS Møller - 2016 - [相关文章](#)

2016年6月29日 - Inhibition of **KCa3.1** aggravated **liver** fibrosis during carbon ... hepatocyte apoptosis and DNA **damage**, whereas proliferation of hepatic ... this channel appears to be **anti-fibrotic** and protective during **liver** injury. **Effects** of the **KCa3.1 channel inhibitor Senicapoc** in CCl4 induced hepatic injury in wt mice.

Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis

<https://www.ncbi.nlm.nih.gov> › NCBI › Literature › PubMed Central (PMC) - [翻译此页](#)

作者 : R Vuppalanchi - 2009 - 被引用次数 : 572 - [相关文章](#)

Nonalcoholic fatty liver disease (NAFLD) is **one** of the most common causes of ... Low titers of **anti-smooth muscle** and **anti-mitochondrial** antibodies may also be noted The ELF is essentially the "Original European Liver **Fibrosis**" (OELF) test histology in patients with **NASH** although their favorable **effect** on **steatosis** is ...

缺少字词 : **kca3 channel senicapoc**

JournalTOCs

www.journaltoCs.ac.uk › Browse by Publisher ▼ [翻译此页](#)

We treated H460 cells, a **non-small-cell lung cancer** cell line, with amitriptyline ... Thus, our finding demonstrated that the **liver** growth **inhibitory effect** of NR1C3 MicroRNAs-mediated epithelial-mesenchymal transition in **fibrotic diseases** ... Thus, 9R-P201 holds great potential as a lead **anti-cancer** drug targeting FoxM1.